Ado-trastuzumab emtansine is a HER2-targeted antibody-drug conjugate which contains the humanized anti-HER2 IgG1, trastuzumab, covalently linked to the microtubule inhibitory drug DM1 via the stable thioether linker MCC. Trastuzumab is produced by Chinese hamster ovary cells, and DM1-MCC are produced by chemical synthesis. Ado-trastuzumab emtansine contains an average of 3.5 DM1 molecules per antibody.
Ado-trastuzumab emtansine is supplied at a concentration of 20 mg/mL as a sterile, clear and colorless, preservative-free solution, which contains polysorbate 20 [0.02% (w/v)], sodium succinate (10 mM), and sucrose [6% (w/v)] with a pH of 5.0.
|
Name
|
Ado-trastuzumab emtansine
|
|
CAS NO.
|
1018448-65-1
|
|
Type
|
Whole antibody
|
|
Source
|
humanized (from mouse)
|
|
Target
|
HER2
|
|
Clone
|
Monoclone
|
|
Formula
|
C6448H9948N1720O2012S44
|
|
Molecular Weight
|
149 kDa
|
|
Antibody Form
|
Purified immunoglobulin
|
|
Physical Form
|
Solution
|
|
Grade Standard
|
Medicine Grade
|
|
Place of Origin
|
China (Mainland)
|
|
Storage
|
-70±15℃ for long-term storage, 2-8℃ for short-term storage, away from light.
|
bio-equip.cn
Shanghai Topwell Pharma Co., Ltd. is specialized in research, development, custom manufacturing and sales of Pharmaceutical Intermediates, APIs, Pharmaceutical Excipients, Health & Nutritional Ingredients, Polypeptides and Antibodies, etc..
Topwell has a professional R&D team. We have built close cooperative relationships with many research institutes and universities in China. In addition, we have very close cooperation relationships with many Chinese pharmaceutical factories.
Topwell aims to become a global leader in pharmaceutical & chemical industry.
中文
